An assessment of the prophylactic and ameliorative effects of deoxyspergualin (NKT-01), an immunosuppressive agent, was carried out in male MRL/MpJ-lpr/lpr (MRL/1) mice which spontaneously develop lupus-like lesions. When NKT-01 was administered ip daily from the age of either 8 or 19 weeks, diseases such as massive lymphadenopathy, circulating anti-DNA antibody and lupus nephritis were markedly suppressed. The primary response to lipopolysaccharide was significantly reduced in MRL/1mice administered NKT-01but the response to sheep red blood cells was not affected. The ability of spleen cells to release interleukins 2 and 3 with or without mitogen was significantly enhanced in mice receiving NKT-01.These findings demonstrate that NKT-01has therapeutic activity against the development of spontaneous disease in MRL/1 mice.
Deoxyspergualin (NKT-01) is a derivative of spergualin, a metabolite of Bacillus laterosporusD shown to have immunosuppressive activities in rodents2). This derivative, with a molecular weight of 496.9 and a moiety bearing a spermidine and a guanidinic group, has been found to suppress antibody production and delayed-type hypersensitivity to sheep red blood cells (SRBC) and to have a stronger activity than spergualin in inhibiting the rejection of skin allografts in rats3). In mice, NKT-01 inhibits the development of graft-versus-host disease43. In rats, NKT-01 inhibits the rejection of heart5), liver6), kidney7) and pancreas8) allografts. The purpose of the present study is to examine whether NKT-01can prevent the spontaneous development of autoimmune disease and affect the immune response, when administered to male MRL/MpJ-lpr/lpr (MRL/1) mice.
Materials and Methods

Animals
Male MRL/1and MRL/MpJ-+/-f (MRL/+) mice were purchased from Jackson Laboratories, Bar Harbor, U.S.A. Treatment NKT-01 was supplied by Takara Shuzo Co., Ltd., dissolved in saline and sterilized by passing through a 0.22-/mi filter. In a previous experiment, when NKT-01was administered ip daily at an immunosuppressive dose of 3 mg/kg from week 12, weight loss was observed about 6 weeks after the initial administration of NKT-01. Therefore, the dose was lowered to 1.5 mg/kg in all experiments. SEPT. 1988 Measurement of Anti-DNA Antibody by Enzyme-linked Immunosorbent Assay (ELISA) ELISA was carried out using modified methods of Eaton et «/.9) and Godfrey et al.10K An aliquot (0.3 ml) of 0.05 % aqueous solution of poly-L-lysine was incubated in a Nunc ELISA plate for 1.5 hours at room temp. The plates were washed using phosphate buffered saline with 0.1 %gelatin (PBS-G) as the washing and diluting buffer, and 0.2 ml of calf thymus DNA(5 /*g/ml PBS-G; Sigma, St. Louis, U.S.A.) was added. After incubating overnight at 37°C, any free sites were blocked by incubating with 0.2% bovine serum albumin for 1 hour at 37°C. A 0.2-ml aliquot of an 1/200-dilution of each mouse serum was then added and the plates were incubated for 1.5 hours at 37°C. The plates were then washed, and 0.2 ml of an 1/1,000-dilution of goat anti-mouse IgG serum (Cappel, Cochranville, U.S.A.) was added and incubated for 1.5 hours at 37°C. After washing, an 1/1,000-dilution (0.2 ml) of alkaline phosphatase-conjugated rabbit anti-goat IgG serum (Cappel) was added and incubated 1.5 hours at 37°C. Finally, 0.2 ml of^-nitrophenyl phosphate (Sigma), 2 mg/ml in 10%diethanolamine buffer, pH 9.8, was added and after 1 hour incubation at room temp, the absorbance ofi?-nitrophenyl was measured at 410 nm.
Blood Urea Nitrogen (BUN) BUNwas estimated by the urease-indophenol method using a Rapid Blood Analyzer Super (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan).
Histology
Kidneys were fixed in 10%buffered formalin and sectioned. The sections were stained with hematoxylin-eosin, periodic acid shiff, Masson and fibrin-staining methods for histopathological examinations. Twenty-five glomeruli were observed per section and the degree of glomerular damage was indicated by a pathological score based on the severity of change where 0=no, 1 ==minimal, 2= slight, 3 =moderate and 4=severe.
Plaque-forming Cells (PFC) Assay PFC producing antibody to SRBC (Nippon Biosupp Center, Tokyo, Japan) and Escherichia coli 055 : B5 lipopolysaccharide (LPS ; Difco, Detroit, U.S.A.) were enumerated according to Cunningham and Szenberg1i:). PFC producing anti-LPS were measured using LPS-coated SRBCas indicator cells.
Production of Interleukins 2 (IL 2) and 3 (IL 3) RPMI 1640 medium supplemented with 10% fetal calf serum, streptomycin (100^g/ml) and benzylpenicillin (100 u/ml) was used to incubate spleen cells from each MRL/1mouse at 37°C in 5 % COgin air. To prepare culture supernatants containing IL 2 and IL 3, the spleen cells (5 x 106 cells/ml/ well) were incubated with or without 2.5^g/ml of concanavalin A (Con A; Sigma) in 24-well Costar culture plates. After 48 hours incubation the supernatants were separated. The presence of IL 2 and IL 3 was assayed by the ability of the supernatants to support proliferation of IL 2-dependent cell line CTLL-212) and IL 3-dependent cell line FDC-P213) that was provided by Dr. K. Kumagai, Tohoku University, Japan, respectively.
Statistical Analysis
All data were analyzed by Student's t-test.
Results
MRL/1mice spontaneously develop massive lymphadenopathy, circulating antinuclear antibody, increased BUNand glomerulonephritis. Results obtained in mice that were 8 weeks old at the beginning of the prophylactic study of NKT-01are shown in Table 1 . At the age of22 weeks and completion of the NKT-01administration, all parameters were significantly suppressed in mice receiving NKT-01. In contrast, there was an insignificant decrease in body weight between control mice (mean= 49.1 g) and NKT-01 treated mice (mean=48.5 g).
In a second series of experiment, we examined the curative use of NKT-01.NKT-01was ad- NKT-01 was administered ip daily for 4 weeks followed by a 1-week interval and this was repeated 3 times from week 8 through 22. During the 2 intervening weeks no NKT-01was given. A set of control MRL/1mice receiving saline was included. The mice were sacrificed on the day after completion of the NKT-01administration and lymph nodes, spleens, blood and kidneys were removed. The mesenteric, axillary, elbow, inguinal, submaxillary lymph nodes were pooled individually. Data are shown as mean± SD. * P<0.01. The testing conditions were the same as those described in Table 2 . Each bar shownis a meanvalue. SEPT. 1988 (Fig. 1A) . In contrast, an nonsignificant increase in the BUN level was observed in NKT-01 treated mice (an initial mean of 35.2mg/dl; a final mean of 41.0mg/dl). However, after this 24-day regimen, an abnormal BUNwas seen only in a few control mice and the number of mice with an abnormal BUN score was similar in NKT-01 treated mice. The NKT-01 treated mice had a mean anti-DNA titer of 0.53 at week 19 which significantly (P<0.005) decreased to a mean of0.27 by week 22 (Fig. IB) . This reduced level of anti-DNA titer at 22 weeks in treated mice was also significantly (P<0.005) less than that of control (mean=0.59) (Fig. IB) . Ten-week old MRL/1 mice were used. NKT-01 was administered ip daily for 42 days. The day after completing NKT-01administration spleens were removed. Both IL 2 and IL 3 activities in supernatants from the spleen cells with or without GonA stimulation were quantitated in the presence of 1 x 104 CTLL-2 or FDC-P2 cells in a final volume of 0.2ml. These cells were incubated for 24 hours, pulsed with 1 lid of [6-3H] Similarly, total lymph node and spleen weights, and the degree of glomerular damage were significantly reduced by the administration of NKT-01to these mice ( Table 2) .
As shown in Table 3 , control MRL/1mice showed poor primary response to SRBCand normal response to LPS compared with nonautoimmune MRL/+mice. We examined whether NKT-01 could affect these responses in MRL/1mice. NKT-01did not affect the primary response to SRBC but significantly inhibited antibody production against LPS.
The spleen cells from control MRL/1mice released little IL 2 and abnormal amounts of IL 3 in the presence or absence of Con A ( Table 4 ). The ability to release IL 2 and IL 3 of spleen cells with or without Con A was significantly enhanced by the NKT-01administration.
Discussion
The prophylactic administration of NKT-01with ip doses of 1 mg/kg has been shown to prevent organ rejection in various allo-transplantation models and experimental allergic encephalomyelitis in guinea pigs14). Therefore, we predicted that the treatment of 8 week old MRL/1mice with this drug might prevent the appearance of their autoimmunediseases. Although the prophylactic administration of NKT-01 at an immunosuppressive dose of 3 mg/kg induced severe body weight loss, NKT-01 at a lower dose of L5 mg/kg used here markedly inhibited the development of their autoimmune diseases without toxicity.
Of particular interest was whether this immunosuppressive agent could stop or ameliorate autoimmune disease in MRL/1mice suffering advanced spontaneous diseases. Those animals which initially had high anti-DNA titer showed significantly decreased levels, when given NKT-01 for only 24 days from the age of 19 weeks. The NKT-01therapy also resulted in decreased glomerular damage. The effectiveness of NKT-01in decreasing the anti-DNA titer was further substantiated by a suppression of antibody production to the T-independent antigen LPS. Since the administration period of NKT-01was only 24 days in the present curative study, its long-term administration needs to be examined to determine the prolonged amelioration of autoimmune diseases and an extension of life span. Control MRL/1mice have also been shown to manifest not only a poor primary response to SRBC15) but also a defective ability to release IL 2 after Con A stimulation16>17). Although NKT-01 did not affect antibody production to SRBC, both spontaneous and Con A-stimulated IL 2 release were enhanced in MRL/1mice receiving NKT-01. Significantly, the defective ability of IL 2 release following Con A stimulation was effectively restored by NKT-01administration. Palacios proposed that an abnormal production of IL 3 accounted for the outgrowth of nonmalignant T cells responsible for lymphadenopathy in MRL/1mice18). Since, in the present studies, NKT-01 led to a significant reduction in lymphadenopathy in MRL/1mice, we naturally expected that this agent would suppress IL 3 release. Contrary to our expectation, a significant enhancementof IL 3 release with or without Con A was observed. Therefore, NKT-01is suggested to suppress lymphadenopathy independently of IL 3 production.
As NKT-01 very rapidly hydrolyzes under usual culture conditions, it is difficult to examine the mode of NKT-01action in vitro. At present, there is no evidence showing an in vitro effect of NKT-01 at physiological concentrations (<1^g/ml). Recently, Dickneite et al. demonstrated that NKT-01 administration suppresses the chemiluminescence reaction of blood monocytes and not the blastogenic response of blood lymphocytes in rats19). Wefound that NKT-01enhances the function of spleen cells in the blastogenic response, or in the release of IL 1 and IL 2 in skin-allografted rats20). Morerecently, NKT-01 was demonstrated to ameliorate ongoing rejection in rat allogeneic heart transplantation2x) and advancing graft-versus-host disease in mice22). In xenogeneic (hamster to rat) heart transplantation, this agent was found to be more effective than cyclosporine in prolonging graft survival235. While the mechanisms responsible for the immunosuppression elicited by NKT-01re-main to be unravelled, it is likely that these will be different from those of cyclosporine.
In conclusion, NKT-01is beneficial as both a prophylactic and a curative therapy for lupus-like SEPT. 1988 lesions in MRL/1mice. Although a mechanism linking the therapeutic activity of NKT-01and NKT-01-induced immunosuppression in these autoimmune disease mice is not clear, both an impairment of B cell function and an enhancement of IL production by NKT-01 may in part be likely mechanisms for these effects. However, further studies on the mechanism of NKT-01action in this model are needed.
